Normokalemic periodic paralysis

Summary

Normokalemic periodic paralysis (MONDO:0008225) is a disease. A subtype of familial periodic paralysis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	normokalemic periodic paralysis
Mondo ID	MONDO:0008225
OMIM	170600
Orphanet	680
NCIT	C122791
SNOMED CT	40381009
UMLS	C0268445
MedGen	78678
GARD	0004009
Is cancer (heuristic)	no

Also known as: normokalemic periodic paralysis · normokalemic PP · NormoKPP · periodic paralysis type 3 · potassium-sensitive normokalemic periodic paralysis

Disease family

This is a subtype of familial periodic paralysis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inborn errors of metabolism › inborn metal metabolism disorder › familial periodic paralysis › normokalemic periodic paralysis

Related subtypes (5): Andersen-Tawil syndrome, hypokalemic periodic paralysis, hyperkalemic periodic paralysis, periodic paralysis with later-onset distal motor neuropathy, thyrotoxic periodic paralysis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.